These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22475049)

  • 1. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
    Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
    BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
    Huan Y; Jiang Q; Liu JL; Shen ZF
    J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
    Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
    J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
    Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
    Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP4 inhibitors for diabetes--what next?
    Lambeir AM; Scharpé S; De Meester I
    Biochem Pharmacol; 2008 Dec; 76(12):1637-43. PubMed ID: 18755155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
    Zettl H; Schubert-Zsilavecz M; Steinhilber D
    ChemMedChem; 2010 Feb; 5(2):179-85. PubMed ID: 20029928
    [No Abstract]   [Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
    Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
    Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.